LONDON--(BUSINESS WIRE)--The global overactive bladder therapeutics market size is poised to reach USD 300.28 million by 2023, according to a new report by Technavio, progressing at a CAGR of 2% during the forecast period.
Read the 157 page research report with TOC on "Overactive Bladder Therapeutics Market Analysis Report by Product (anticholinergics, Beta-3 adrenergic agonists, and other OAB therapeutics) and geographical regions (North America, Europe, Asia, and ROW) 2019 - 2023" Request Free Sample Pages
The market is driven by the advent of combination therapy which exhibits higher efficacy with fewer side-effects. In addition, increasing number of drug approvals is anticipated to further boost the overactive bladder therapeutics market during the forecast period.
Currently, OAB therapeutics that are available in the market only provide symptomatic relief to patients without curing the disease. Hence, the market has a high unmet need for effective therapeutics for the treatment of OAB. To address this need, Astellas, an established vendor, has introduced the first combination therapy which comprises of Myrbetriq and VESIcare. The launch of combination therapy for the treatment of OAB will offer patients an efficacious pharma logical regime that requires a shorter duration and will decrease the overall cost associated with treatment. The benefits associated with combination therapy for treatment of OAB, will lead to an increase in demand which will drive the growth of the market during the forecast period.
Furthermore, the global OAB therapeutics market is witnessing an increase in the number of drug approvals due to the LOE of major drugs. A tentative approval is granted to a generic drug until all the patent exclusivity issues related to the original drug have been resolved. Although an applicant needs to receive final approval from the US FDA to market its drug, tentative approvals help market the drug as soon as the patent expires. Therefore, the market is witnessing the approval of generics by the US FDA and the launch of second beta-3 adrenergic agonists for the treatment of OAB. These approvals have increased the volume consumption of OAB therapeutics in the past few years and are expected to further drive market growth over the forecast period.
For More Information: Request Free Sample Pages
The report includes detailed profiles of the leading companies & prominent vendors of the market:
- AbbVie Inc.
- Astellas Pharma Inc.
- Camber Pharmaceuticals Inc.
- Endo International Plc
- KYORIN Holdings Inc.
- Merck & Co. Inc.
- Mylan NV
- Ono Pharmaceutical Co. Ltd.
- Pfizer Inc.
- Teva Pharmaceutical Industries Ltd.
Market Segmentation by Category and Product Types:
The Overactive Bladder Therapeutics market can be broadly categorized into the following product segments:
- Beta-3 adrenergic agonists
- Other OAB therapeutics
Key Regions for the Overactive Bladder Therapeutics Market:
Featuring a breakdown of region wise market shares until 2019.
- North America
Some of the key topics covered in the report include:
- Market ecosystem
- Market characteristics
Market segmentation analysis
- Market definition
Market size and forecast
- Vendors covered
- Vendor classification
- Market positioning of vendors
- Competitive scenario
Technavio’s sample reports are free of charge and contain multiple sections of the report, such as the market size and forecast, drivers, challenges, trends, and more. Request a free sample report
Related Reports on Healthcare Market are:
Neuromuscular Disease Therapeutics Market – Global Neuromuscular Disease Therapeutics Market by type (biologics and small molecules) and geography (Asia, Europe, North America, and ROW).
Femoral Stems Market– Global Femoral Stems Market by fixture (cementless femoral stems and cemented femoral stems) and geography (Asia, Europe, North America, and ROW).
Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.
With over 500 specialized analysts, Technavio’s report library consists of more than 10,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
If you are interested in more information, please contact our media team at firstname.lastname@example.org.